Patents Assigned to ZS Pharma, Inc.
-
Patent number: 11738044Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.Type: GrantFiled: May 17, 2019Date of Patent: August 29, 2023Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 11406662Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: April 16, 2020Date of Patent: August 9, 2022Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 10695365Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: January 23, 2018Date of Patent: June 30, 2020Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 10695366Abstract: The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease.Type: GrantFiled: March 19, 2018Date of Patent: June 30, 2020Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 10413569Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: April 21, 2015Date of Patent: September 17, 2019Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 10398730Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: August 13, 2015Date of Patent: September 3, 2019Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 10335432Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: September 1, 2016Date of Patent: July 2, 2019Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Jeff Gilmore
-
Patent number: 10300087Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.Type: GrantFiled: January 31, 2017Date of Patent: May 28, 2019Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9943637Abstract: The present invention relates to novel microporous zirconium silicate compositions having a desired particle size distribution and methods of making those compositions. These compositions have an ideal particle size distribution for use ex vivo, for example in a dialysis exchange cartridge, yet retain many of the desirable properties of prior improved absorbers including high cation exchange capacity. Further, the new zirconium silicate molecular sieve absorbers can be manufactured using a technique that achieves the desired particle size distribution while eliminating the screening step that was previously necessary.Type: GrantFiled: March 14, 2013Date of Patent: April 17, 2018Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9913860Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: February 20, 2015Date of Patent: March 13, 2018Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9861658Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: August 13, 2015Date of Patent: January 9, 2018Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9844567Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: July 1, 2014Date of Patent: December 19, 2017Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9707255Abstract: The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without removing calcium from the patient's body. Also disclosed are methods of using calcium-free or low calcium microporous zirconium silicate compositions for the treatment of hyperkalemia in patients also suffering from hypercalcemia.Type: GrantFiled: July 11, 2013Date of Patent: July 18, 2017Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9662352Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: July 1, 2014Date of Patent: May 30, 2017Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9592253Abstract: The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.Type: GrantFiled: October 14, 2015Date of Patent: March 14, 2017Assignee: ZS PHARMA, INC.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 9457050Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: March 26, 2014Date of Patent: October 4, 2016Assignee: ZS Pharma, Inc.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Jeff Gilmore
-
Patent number: 8877255Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: October 22, 2013Date of Patent: November 4, 2014Assignee: ZS Pharma, Inc.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Publication number: 20140302175Abstract: The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease.Type: ApplicationFiled: April 3, 2014Publication date: October 9, 2014Applicant: ZS Pharma, Inc.Inventors: Donald Jeffrey KEYSER, Alvaro F. GUILLEM
-
Patent number: 8808750Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: September 25, 2013Date of Patent: August 19, 2014Assignee: ZS Pharma, Inc.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem
-
Patent number: 8802152Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.Type: GrantFiled: February 10, 2012Date of Patent: August 12, 2014Assignee: ZS Pharma, Inc.Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem